We’re redefining healthcare by rewilding the gut ecosystem. Our proprietary CONSORTIOME® platform is powering next-generation co-cultured therapeutics, positioning us as a global leader in the field. We invite you to unlock the full potential of microbiome medicine with us.
We’re not just advancing a new area of science — we’re building the foundation for an entirely new category of medicine.
BiomeBank was the first to deliver a regulated donor-derived microbiome therapy — a breakthrough that has already set us apart in a rapidly emerging, multi-billion-dollar global market.
Today, we’re building scalable next-generation microbiome therapeutics with our CONSORTIOME® platform.
BiomeBank holds a defensible leadership position at this rare inflection point with:
This technology is treating gut disease with emerging potential to address multiple major health areas from liver, infection control and cancer therapy support through to immune, metabolic, neurological and even cardiovascular health.
Join us in reshaping the future of human health.
Like many thriving ecosystems found in nature, diversity is the key ingredient for a healthy gut microbiota. Modern lifestyles and environments are causing gut bacterial diversity to decline, and this is associated with the rise of numerous chronic diseases.
BiomeBank is at the forefront of developing therapies that harness the power of ecology and technology to engineer an ecologically diverse consortia of microbes carrying that specific mechanism of action, as well as emergent therapeutic properties that manifest at the community level.
Annotation using the NCBI COG database (”Clusters of Orthologous Genes”) identified members of 1775 gene families from a healthy donor metagenome, of which over 90% of gene families were represented in the consortium metagenome.
WATCH: CEO and Co-founder Dr Sam Costello explain BiomeBank’s
revolutionary CONSORTIOME® Technology in more detail (2min)
The global microbial therapeutic market is projected to reach a valuation of US$30 billion by 2030, making the gut microbiome a new frontier in medicine.
BiomeBank’s breakthrough co-culturing technology mean it is well-positioned to become a global leader in the sector. Our first such co-cultured therapy, BB265 for ulcerative colitis, has been designed using data from use of BiomeBank’s donor derived therapy in clinical trials and entered human trials in 2024.
10% market penetration = $1.3 billion per year
A snapshot of
ulcerative colitis
In 2021 sales of treatments for ulcerative colitis in 2021 totalled $7.3B. By 2032 the Total Addressable Market (TAM) is expected to reach $13.0B annually.1
Current therapies are inadequate with 30-35% remission rates and a 10-40% loss of response in patients. Also, many existing therapies for UC have risks of adverse events related to immune suppression, resulting in a large unmet medical need. 2
BiomeBank’s BB265 is formulated to disrupt the UC market and to provide a better solution patients with ulcerative colitis.
1. Global data UC report 2023;
2 Savelkoul et al Inflamm bowel dis 2022
BiomeBank has strong track record of commercialisation. Our donor-derived microbiome therapy was the first regulator-approved microbial therapy in the world.
We are currently supplying this product to physicians based in Australia to treat patients with C. difficile infection.
BiomeBank is now leveraging the real-world, human data collected from these therapies as well as employing our cutting-edge CONSORTIOME® platform to engineer and test a pipeline of novel, co-cultured microbial therapies.
Identify
Leveraging real-world, human data from our existing therapies to establish the causation of disease, our ‘human-first’ model of discovery allows us to more rapidly and precisely identify the ‘mechanism of action’ when compared to animal models.
Develop
Harnessing the latest technology, we mine real-world data and select candidate strains from our leading culture collection. Employing our cutting-edge CONSORTIOME® platform, we engineer an ecologically diverse consortia of microbes carrying that specific mechanism of action, as well as emergent therapeutic properties that manifest at the community level.
Optimise
Delivering BiomeBank potential drug candidates with the highest chance of clinical success.
Please get in touch if you’d like more information about BiomeBank and the potential for investing in the future of medicine.